This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Hormonal Profile (LH, FSH, Testosterone) from Baseline
Timeframe: Baseline and 3 months after starting assigned treatment
Change in Glycemic Control Markers (Fasting Glucose, Insulin, HOMA-IR) from Baseline
Timeframe: Baseline and 3 months after starting assigned treatment
Mohammed Mahmood Mohammed, professor